外傷性脳損傷(TBI)分析のグローバル市場(2021~2031):病院、診断センター、その他

■ 英語タイトル:Traumatic brain injuries assessment Market By End-user (Hospital, Diagnostics Center, Others), By Diagnostic Type (CT-Scan, MRI, Intracranial Pressure Monitoring, Partial Pressure of Oxygen in Brain Tissue (pBrO2), Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート(データ管理コード:ALD23MC100)■ 発行会社/調査会社:Allied Market Research
■ 商品コード:ALD23MC100
■ 発行日:2023年1月
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:250
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Online Only(1名閲覧、印刷不可)USD3,570 ⇒換算¥542,640見積依頼/購入/質問フォーム
Single User(1名閲覧)USD5,730 ⇒換算¥870,960見積依頼/購入/質問フォーム
Enterprise User(閲覧人数無制限)USD9,600 ⇒換算¥1,459,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[外傷性脳損傷(TBI)分析のグローバル市場(2021~2031):病院、診断センター、その他]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Allied Market Research社の調査資料では、2021年には9,570百万ドルであった世界の外傷性脳損傷(TBI)分析市場規模が2031年には18,373.6百万ドルへ及び、予測期間中にCAGR 7.0%増加すると推測されています。本調査資料では、外傷性脳損傷(TBI)分析の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、エンドユーザー別(病院、診断センター、その他)分析、診断種類別(CTスキャン、MRI、頭蓋内圧モニタリング、脳組織内酸素分圧(pBrO2)、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ)分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、brainscope company inc.、NOVASIGNAL CORPORATION、Integra LifeSciences Holdings Corporation、Natus Medical Incorporated、Boston Scientific Corporation、Koninklijke Philips N.V.、BioDirection, Inc.、Nihon Kohden Corp.、RAUMEDIC AG、Compumedics Ltd.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の外傷性脳損傷(TBI)分析市場規模:エンドユーザー別
- 病院における市場規模
- 診断センターにおける市場規模
- その他エンドユーザーにおける市場規模
・世界の外傷性脳損傷(TBI)分析市場規模:診断種類別
- CTスキャンにおける市場規模
- MRIにおける市場規模
- 頭蓋内圧モニタリングにおける市場規模
- 脳組織内酸素分圧(pBrO2)における市場規模
- その他診断における市場規模
・世界の外傷性脳損傷(TBI)分析市場規模:地域別
- 北米の外傷性脳損傷(TBI)分析市場規模
- ヨーロッパの外傷性脳損傷(TBI)分析市場規模
- アジア太平洋の外傷性脳損傷(TBI)分析市場規模
- 中南米/中東・アフリカの外傷性脳損傷(TBI)分析市場規模
・競争状況
・企業情報

世界の外傷性脳損傷(TBI)分析市場規模は2021年に95億7,000万ドル、2031年までに183億7,360万ドルの収益を生み出すと予測されており、CAGRは7.0% %となる見込みです。

外傷性脳損傷(TBI)分析市場の成長は、インドの重要な公衆衛生問題です。外傷性脳損傷は、若く活動的な社会構成員の死亡、危害、障害に寄与しています。インドでは、TBIによって莫大な経済的損失が発生していますが、その損失は定量化できません。インドでは、モータリゼーションと都市化の進展に伴い、TBIが増加することが予想されます。世界保健機関(WHO)が最近発表した交通事故死傷防止と暴力と健康に関する世界報告書は、世界中で傷害の問題がいかに深刻になっているかを明らかにし、予防、管理、リハビリテーションのためのプログラムを緊急に立案し、評価する必要があることを示しています。インドは予防を優先していない国のひとつです。

TBIは実行機能と自制心に悪影響を及ぼします。ストレスや不安に関連した行動をコントロールする能力は、自己制御として知られています。TBIを受けた人の場合、落ち着くことが難しかったり、順番を待つことが難しかったり、見知らぬ環境で感情が高ぶったりすることがあります。実行機能とは、計画、記憶、目標の設定、注意の集中、指示に従うことなどに関与する高次の脳機能を指します。TBIの患者さんは、容易に方向感覚を失ったり、物事を忘れたりすることがあり、新しい情報を学んだり、書類仕事をこなしたり、公共交通機関を利用したりすることに困難を感じることがあります。

市場参入企業による最新技術の採用や新製品の発売は、予測期間中の市場拡大を加速させる見込みです。例えば、Bio Direction, Inc.のNanoDxシステムは、脳震盪/TBIを2分以内に正確に診断する迅速なポイントオブケア(POC)診断薬です。

National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)から資金提供を受けているこの研究はまだ進行中ですが、予備的な知見によると、パンデミックは、社会的孤立、日常生活の混乱、認知への影響など、脳損傷を受けた人々に大きな影響を与えることが示されています。地域生活支援局(Administration for Community Living)が資金提供する外傷性脳損傷技術支援・資料センター(TBI TARC)は、COVID-19が脳損傷者にどのような影響を与えたかをさらに調査することに着手しました。TBI Advisory and Leadership(TAL)グループの5人のメンバーは、TBI TARCから質問を受けました。TALグループの目的は、TBI TARCの優先事項を指示することです。

本レポートに掲載されている主要企業は、Integra Lifesciences、BioDirection, Inc.、日本光電工業、Compumedics Ltd.、InfraScan, Inc.、Oculogica、Raumedic AG、Zagros Petrochemical Co.、Koninklijke Philips N.V.、Boston Scientific Corporation、Elektaなどです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの外傷性脳損傷(TBI)分析市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、外傷性脳損傷(TBI)分析市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・外傷性脳損傷(TBI)分析市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域および世界の外傷性脳損傷(TBI)分析市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
エンドユーザー別
病院
診断センター
その他

診断タイプ別
CTスキャン
MRI
頭蓋内圧モニタリング
脳組織内酸素分圧(pBrO2)
その他

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
イギリス
フランス
スペイン
イタリア
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
アラブ首長国連邦
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
brainscope company inc.
NOVASIGNAL CORPORATION
Integra LifeSciences Holdings Corporation
Natus Medical Incorporated
Boston Scientific Corporation
Koninklijke Philips N.V.
BioDirection, Inc.
日本光電工業株式会社
RAUMEDIC AG
Compumedics Ltd.

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
3.6.Value Chain Analysis
3.7.Key Regulation Analysis
3.8.Patent Landscape
3.9.Regulatory Guidelines
3.10.Market Share Analysis
CHAPTER 4: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER
4.1 Overview
4.1.1 Market size and forecast
4.2. Hospital
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Diagnostics Center
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2. CT-Scan
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. MRI
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4. Intracranial Pressure Monitoring
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
5.5. Partial Pressure of Oxygen in Brain Tissue (pBrO2)
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market share analysis by country
5.6. Others
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market share analysis by country
CHAPTER 6: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by End-user
6.2.3 North America Market size and forecast, by Diagnostic Type
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by End-user
6.2.4.1.3 Market size and forecast, by Diagnostic Type
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by End-user
6.2.4.2.3 Market size and forecast, by Diagnostic Type
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by End-user
6.2.4.3.3 Market size and forecast, by Diagnostic Type
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by End-user
6.3.3 Europe Market size and forecast, by Diagnostic Type
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by End-user
6.3.4.1.3 Market size and forecast, by Diagnostic Type
6.3.4.2 UK
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by End-user
6.3.4.2.3 Market size and forecast, by Diagnostic Type
6.3.4.3 France
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by End-user
6.3.4.3.3 Market size and forecast, by Diagnostic Type
6.3.4.4 Spain
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by End-user
6.3.4.4.3 Market size and forecast, by Diagnostic Type
6.3.4.5 Italy
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by End-user
6.3.4.5.3 Market size and forecast, by Diagnostic Type
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by End-user
6.3.4.6.3 Market size and forecast, by Diagnostic Type
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by End-user
6.4.3 Asia-Pacific Market size and forecast, by Diagnostic Type
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by End-user
6.4.4.1.3 Market size and forecast, by Diagnostic Type
6.4.4.2 Japan
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by End-user
6.4.4.2.3 Market size and forecast, by Diagnostic Type
6.4.4.3 India
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by End-user
6.4.4.3.3 Market size and forecast, by Diagnostic Type
6.4.4.4 South Korea
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by End-user
6.4.4.4.3 Market size and forecast, by Diagnostic Type
6.4.4.5 Australia
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by End-user
6.4.4.5.3 Market size and forecast, by Diagnostic Type
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by End-user
6.4.4.6.3 Market size and forecast, by Diagnostic Type
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by End-user
6.5.3 LAMEA Market size and forecast, by Diagnostic Type
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by End-user
6.5.4.1.3 Market size and forecast, by Diagnostic Type
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by End-user
6.5.4.2.3 Market size and forecast, by Diagnostic Type
6.5.4.3 UAE
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by End-user
6.5.4.3.3 Market size and forecast, by Diagnostic Type
6.5.4.4 South Africa
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by End-user
6.5.4.4.3 Market size and forecast, by Diagnostic Type
6.5.4.5 Rest of LAMEA
6.5.4.5.1 Key market trends, growth factors and opportunities
6.5.4.5.2 Market size and forecast, by End-user
6.5.4.5.3 Market size and forecast, by Diagnostic Type
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
8.1 brainscope company inc.
8.1.1 Company overview
8.1.2 Key Executives
8.1.3 Company snapshot
8.1.4 Operating business segments
8.1.5 Product portfolio
8.1.6 Business performance
8.1.7 Key strategic moves and developments
8.2 NOVASIGNAL CORPORATION
8.2.1 Company overview
8.2.2 Key Executives
8.2.3 Company snapshot
8.2.4 Operating business segments
8.2.5 Product portfolio
8.2.6 Business performance
8.2.7 Key strategic moves and developments
8.3 Integra LifeSciences Holdings Corporation
8.3.1 Company overview
8.3.2 Key Executives
8.3.3 Company snapshot
8.3.4 Operating business segments
8.3.5 Product portfolio
8.3.6 Business performance
8.3.7 Key strategic moves and developments
8.4 Natus Medical Incorporated
8.4.1 Company overview
8.4.2 Key Executives
8.4.3 Company snapshot
8.4.4 Operating business segments
8.4.5 Product portfolio
8.4.6 Business performance
8.4.7 Key strategic moves and developments
8.5 Boston Scientific Corporation
8.5.1 Company overview
8.5.2 Key Executives
8.5.3 Company snapshot
8.5.4 Operating business segments
8.5.5 Product portfolio
8.5.6 Business performance
8.5.7 Key strategic moves and developments
8.6 Koninklijke Philips N.V.
8.6.1 Company overview
8.6.2 Key Executives
8.6.3 Company snapshot
8.6.4 Operating business segments
8.6.5 Product portfolio
8.6.6 Business performance
8.6.7 Key strategic moves and developments
8.7 BioDirection, Inc.
8.7.1 Company overview
8.7.2 Key Executives
8.7.3 Company snapshot
8.7.4 Operating business segments
8.7.5 Product portfolio
8.7.6 Business performance
8.7.7 Key strategic moves and developments
8.8 Nihon Kohden Corp.
8.8.1 Company overview
8.8.2 Key Executives
8.8.3 Company snapshot
8.8.4 Operating business segments
8.8.5 Product portfolio
8.8.6 Business performance
8.8.7 Key strategic moves and developments
8.9 RAUMEDIC AG
8.9.1 Company overview
8.9.2 Key Executives
8.9.3 Company snapshot
8.9.4 Operating business segments
8.9.5 Product portfolio
8.9.6 Business performance
8.9.7 Key strategic moves and developments
8.10 Compumedics Ltd.
8.10.1 Company overview
8.10.2 Key Executives
8.10.3 Company snapshot
8.10.4 Operating business segments
8.10.5 Product portfolio
8.10.6 Business performance
8.10.7 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 2. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR HOSPITAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR DIAGNOSTICS CENTER, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 4. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 6. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR CT-SCAN, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR MRI, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR INTRACRANIAL PRESSURE MONITORING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR PARTIAL PRESSURE OF OXYGEN IN BRAIN TISSUE (PBRO2), BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 13. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 16. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 17. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 18. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 20. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 21. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 22. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 25. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 26. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 27. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 29. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 30. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 31. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 33. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 34. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 35. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 37. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 39. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 40. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 42. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 44. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 46. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 48. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 50. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 52. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 54. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 55. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 57. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 59. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 61. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. BRAINSCOPE COMPANY INC.: KEY EXECUTIVES
TABLE 65. BRAINSCOPE COMPANY INC.: COMPANY SNAPSHOT
TABLE 66. BRAINSCOPE COMPANY INC.: OPERATING SEGMENTS
TABLE 67. BRAINSCOPE COMPANY INC.: PRODUCT PORTFOLIO
TABLE 68. BRAINSCOPE COMPANY INC.: NET SALES
TABLE 69. BRAINSCOPE COMPANY INC.: KEY STRATERGIES
TABLE 70. NOVASIGNAL CORPORATION: KEY EXECUTIVES
TABLE 71. NOVASIGNAL CORPORATION: COMPANY SNAPSHOT
TABLE 72. NOVASIGNAL CORPORATION: OPERATING SEGMENTS
TABLE 73. NOVASIGNAL CORPORATION: PRODUCT PORTFOLIO
TABLE 74. NOVASIGNAL CORPORATION: NET SALES
TABLE 75. NOVASIGNAL CORPORATION: KEY STRATERGIES
TABLE 76. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
TABLE 77. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 78. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: OPERATING SEGMENTS
TABLE 79. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
TABLE 80. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET SALES
TABLE 81. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATERGIES
TABLE 82. NATUS MEDICAL INCORPORATED: KEY EXECUTIVES
TABLE 83. NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
TABLE 84. NATUS MEDICAL INCORPORATED: OPERATING SEGMENTS
TABLE 85. NATUS MEDICAL INCORPORATED: PRODUCT PORTFOLIO
TABLE 86. NATUS MEDICAL INCORPORATED: NET SALES
TABLE 87. NATUS MEDICAL INCORPORATED: KEY STRATERGIES
TABLE 88. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
TABLE 89. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 90. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 91. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 92. BOSTON SCIENTIFIC CORPORATION: NET SALES
TABLE 93. BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
TABLE 94. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
TABLE 95. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 96. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
TABLE 97. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 98. KONINKLIJKE PHILIPS N.V.: NET SALES
TABLE 99. KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
TABLE 100. BIODIRECTION, INC.: KEY EXECUTIVES
TABLE 101. BIODIRECTION, INC.: COMPANY SNAPSHOT
TABLE 102. BIODIRECTION, INC.: OPERATING SEGMENTS
TABLE 103. BIODIRECTION, INC.: PRODUCT PORTFOLIO
TABLE 104. BIODIRECTION, INC.: NET SALES
TABLE 105. BIODIRECTION, INC.: KEY STRATERGIES
TABLE 106. NIHON KOHDEN CORP.: KEY EXECUTIVES
TABLE 107. NIHON KOHDEN CORP.: COMPANY SNAPSHOT
TABLE 108. NIHON KOHDEN CORP.: OPERATING SEGMENTS
TABLE 109. NIHON KOHDEN CORP.: PRODUCT PORTFOLIO
TABLE 110. NIHON KOHDEN CORP.: NET SALES
TABLE 111. NIHON KOHDEN CORP.: KEY STRATERGIES
TABLE 112. RAUMEDIC AG: KEY EXECUTIVES
TABLE 113. RAUMEDIC AG: COMPANY SNAPSHOT
TABLE 114. RAUMEDIC AG: OPERATING SEGMENTS
TABLE 115. RAUMEDIC AG: PRODUCT PORTFOLIO
TABLE 116. RAUMEDIC AG: NET SALES
TABLE 117. RAUMEDIC AG: KEY STRATERGIES
TABLE 118. COMPUMEDICS LTD.: KEY EXECUTIVES
TABLE 119. COMPUMEDICS LTD.: COMPANY SNAPSHOT
TABLE 120. COMPUMEDICS LTD.: OPERATING SEGMENTS
TABLE 121. COMPUMEDICS LTD.: PRODUCT PORTFOLIO
TABLE 122. COMPUMEDICS LTD.: NET SALES
TABLE 123. COMPUMEDICS LTD.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(ALD23MC100 )"外傷性脳損傷(TBI)分析のグローバル市場(2021~2031):病院、診断センター、その他" (英文:Traumatic brain injuries assessment Market By End-user (Hospital, Diagnostics Center, Others), By Diagnostic Type (CT-Scan, MRI, Intracranial Pressure Monitoring, Partial Pressure of Oxygen in Brain Tissue (pBrO2), Others): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。